阻断CGRP/RAMP1的偏头痛药物减少结直肠和胃瘤的生长,提供快速治疗的可能性. Migraine drugs blocking CGRP/RAMP1 reduce colorectal and stomach tumor growth in studies, offering a fast-track treatment possibility.

澳大利亚研究人员发现,神经信号分子,特别是CGRP及其受体RAMP1, 推动直肠和胃癌的生长。 Australian researchers have found that nerve signaling molecules, particularly CGRP and its receptor RAMP1, drive the growth of colorectal and stomach cancers. 该研究发表在BMJ肿瘤学上,显示这些神经元件帮助肿瘤存活、生长和避免免疫系统。 The study, published in BMJ Oncology, shows these neural components help tumors survive, grow, and evade the immune system. 阻止CGRP或RAMP1使用已经获准供人类使用的偏头痛药物,减少实验中的肿瘤增长,提出一种潜在的新治疗策略。 Blocking CGRP or RAMP1—using migraine drugs already approved for human use—reduced tumor growth in experiments, suggesting a potential new treatment strategy. 调查结果突出表明,通过重新规划现有的药物,有希望、更快地走上临床试验的道路。 The findings highlight a promising, faster path to clinical trials by repurposing existing medications.